Cancer targets and uses thereof
US-2016340425-A1 · Nov 24, 2016 · US
Interferon alpha and omega antibody antagonists
US10358491B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10358491-B2 |
| Application number | US-201816222285-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 17, 2018 |
| Priority date | Jun 23, 2014 |
| Publication date | Jul 23, 2019 |
| Grant date | Jul 23, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to antibodies that broady neutralize interferon-α and interferon-ω, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.
First claim
Opening claim text (preview).
We claim: 1. An isolated polynucleotide encoding an antibody comprising a heavy chain variable region and a light chain variable region, the heavy chain variable region comprising heavy chain complementarity determining region (HCDR) 1 (HCDR1), 2 (HCDR2) and 3 (HCDR3) amino acid sequences of SEQ ID NOs: 109, 113 and 116, respectively, and the light chain variable region comprising light chain complementarity determining region (LCDR) 1 (LCDR1), 2 (LCDR2) and 3 (LCDR3) amino acid sequences of SEQ ID NOs: 82, 94 and 99, respectively. 2. A vector comprising the polynucleotide of claim 1 . 3. An isolated host cell comprising the vector of claim 2 . 4. A method of producing an antibody, comprising culturing the host cell of claim 3 in conditions that the antibody is expressed, and recovering the antibody produced by the host cell. 5. An isolated polynucleotide encoding an antibody comprising a heavy chain variable region (VH) amino acid sequence of SEQ ID NO: 28 and a light chain variable region (VL) amino acid sequences of SEQ ID NO: 150. 6. A vector comprising the polynucleotide of claim 5 . 7. An isolated host cell comprising the vector of claim 6 . 8. A method of producing an antibody, comprising culturing the host cell of claim 7 in conditions that the antibody is expressed, and recovering the antibody produced by the host cell.
Assignees
Inventors
Classifications
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Immunosuppressants, e.g. drugs for graft rejection · CPC title
Drugs for immunological or allergic disorders · CPC title
Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents · CPC title
of the thyroid hormones, e.g. T3, T4 · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10358491B2 cover?
- The present invention relates to antibodies that broady neutralize interferon-α and interferon-ω, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.
- Who is the assignee on this patent?
- Janssen Biotech Inc
- What technology area does this patent fall under?
- Primary CPC classification C07K16/249. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jul 23 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).